P37.34 Outcome Associations with p16, GATA-3, and TTF-1 Clone SP141 IHC Expression in Resected Stage I Lung Squamous Cell Carcinomas

e22010 Background: Tumor hipoxia induces the up-regulation of several genes via the hipoxia-inducible transcription factors (HIF) 1 and 2. HIF-2 alpha (HIF-2 α) and HIF-1 alpha (HIF-1α) are associated with the prognosis of operable NSCLC patients. We studied the immunohistochemical expression of HIF-1α and HIF-2 α in patients with NSCLC and the possible correlation with the maximum standardised uptake value (max SUV) of 18F-FDG as well as other biological parameters. Methods: We used a Tissue Arrayer device (Beecher Instruments. WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3. Sections were scored as positive if >10% of cells stained positively. Staining patterns were correlated to clinical variables. Results: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51). HIF-1α correlated positively with HIF-2 α (p:0,001) and EGFR (p:<0,001) expressions. The maxSUV values of 18F-FDG-PET were higher (p:0,039) in HIF-1α -positive (17,1±8,6) than in negative tumors (11,8±4,4). HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57). HIF-2 α correlated positively with HIF-1α (p:0,001), MIB1 (p:0,045) and EGFR (p:0,091) expressions. After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. Conclusions: 1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage; 2) maxSUVs FDG-PET values were higher in HIF1alpha positive than in HIF-1α negative patients; 3) HIF-1α was correlated with EGFR expression, while HIF-2 α was correlated with MIB1 expression. No significant financial relationships to disclose.

Download Full-text

A Rare Subtype of Non-small Cell Lung Cancer: Report of 159 Resected Stage I-IIIA Pulmonary Lymphoepithelioma-like Carcinoma Cases

10.21203/rs.3.rs-214608/v1 ◽

2021 ◽

Author(s):

Rong-Rong Jiang ◽

Xiao-Meng Dou ◽

Xiao-Li Feng ◽

Wen-Ting Zhu ◽

Man-Xia Guo ◽

...

Keyword(s):

Lung Cancer ◽

Prognostic Factors ◽

Squamous Cell ◽

Cell Lineage ◽

Gene Mutations ◽

Small Cell ◽

Stage I ◽

Driver Gene ◽

Small Cell Lung ◽

Resected Stage

Abstract Background The current study analyzed resected stage I-IIIA pulmonary lymphoepithelioma-like carcinoma (LELC) cases to define the clinical characteristics, prognosis and long-term outcomes of LELC, with the purpose of guiding clinical management for this rare tumor.Methods Resected stage I-IIIA LELC, adenocarcinoma (ADC), squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) cases from our center were enrolled. Propensity score matching (PSM) was applied to minimize the selection bias. Overall survival (OS) and disease-free survival (DFS) were compared between groups. Multivariate analyses were performed to identify the prognostic factors, and a nomogram was developed.Results A total of 159 LELCs, 2,757 ADCs, 1,331 SCCs and 155 ASCs were included. LELC, dominated among younger patients and nonsmokers, always presented without typical imaging manifestations of lung cancer. LELC was a poorly differentiated disease that lacked driver gene mutations and was positive for immunohistochemistry indicators of squamous cell lineage. Survival analyses revealed that OS was significantly better for LELC than for other common non-small cell lung cancer (NSCLC) both before PSM (all P < 0.001) and after PSM (all P < 0.05). Further analyses revealed that early pathological node stage and preoperative albumin level ≥35 were identified as independent prognostic factors favoring OS and DFS.Conclusions LELC, dominated among younger and nonsmoking populations, showed a lower extent of malignancy regarding CT characteristics. It lacked driver gene mutations and was positive for immunohistochemistry indicators of squamous cell lineage. The survival outcome of PSC was better than other common NSCLCs.

Download Full-text

Cytological study of stage I and II squamous cell carcinomas in the oral cavity.

Journal of Japanese Society of Oral Oncology ◽

10.5843/jsot.5.284 ◽

1993 ◽

Vol 5 (3) ◽

pp. 284-289

Author(s):

Mutsumi Uchiyama ◽

Tadamitsu Kameyama ◽

Schunichi Tanaka ◽

Jingo Kusukawa ◽

Tamaka Okina ◽

...

Keyword(s):

Oral Cavity ◽

Squamous Cell ◽

Cytological Study ◽

Squamous Cell Carcinomas ◽

Stage I

Download Full-text

Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer

Journal of Clinical Oncology ◽

10.1200/jco.1999.17.2.668 ◽

1999 ◽

Vol 17 (2) ◽

pp. 668-668 ◽

Cited By ~ 135

Author(s):

Stephen L. Graziano ◽

Gary P. Gamble ◽

Nancy B. Newman ◽

Lynn Z. Abbott ◽

Michelle Rooney ◽

...

Keyword(s):

Median Survival ◽

Squamous Cell ◽

Early Stage ◽

Prognostic Significance ◽

Stage I ◽

Stage Ii ◽

Small Cell Lung ◽

Ras Mutations ◽

Significant Difference ◽

Resected Stage

PURPOSE: The aim of this study was to investigate the prognostic importance of codon 12 K-ras mutations in patients with early-stage non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We identified 260 patients with surgically resected stage I (n = 193) and stage II (n = 67) NSCLC with at least a 5-year follow-up. We performed polymerase chain reaction analysis of DNA obtained from paraffin-embedded NSCLC tissue, using mutation-specific probes for codon 12 K-ras. RESULTS: K-ras mutations were detected in 35 of 213 assessable specimens (16.4%). K-ras mutations were detected in 27 of 93 adenocarcinomas (29.0%), one of 61 squamous cell carcinomas (1.6%), five of 39 large-cell carcinomas (12.8%), and two of 20 adenosquamous carcinomas (10%) (P = .001). G to T transversions accounted for 71% of the mutations. There was no statistically significant difference in overall survival for all patients with K-ras mutations (median survival, 39 months) compared with patients without K-ras mutations (median survival, 53 months; P = .33). There was no statistically significant difference in overall or disease-free survival for subgroups with stage I disease, adenocarcinoma, or non–squamous cell carcinoma or for specific amino acid substitutions. The median survival time for stage II patients with K-ras mutations was 13 months, compared with 38 months for patients without K-ras mutations (P = .03). CONCLUSION: Codon 12 K-ras mutations were more common in adenocarcinomas than in squamous cell carcinomas. For the subgroup with stage II NSCLC, there was a statistically significant adverse effect on survival for the presence of K-ras mutations. However, when the entire group was considered, the presence of K-ras mutations was not of prognostic significance in this cohort of patients with resected early-stage NSCLC.

Download Full-text

Correlation between Skp2 expression and nodal metastasis in Stage I and II oral squamous cell carcinomas

Oral Diseases ◽

10.1111/j.1601-0825.2010.01713.x ◽

2010 ◽

Vol 17 (1) ◽

pp. 102-108 ◽

Cited By ~ 11

Author(s):

P Tosco ◽

G M La Terra Maggiore ◽

P Forni ◽

S Berrone ◽

L Chiusa ◽

...

Keyword(s):

Squamous Cell ◽

Nodal Metastasis ◽

Squamous Cell Carcinomas ◽

Stage I ◽

Oral Squamous Cell Carcinomas ◽

Skp2 Expression

Download Full-text

Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e17538 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e17538-e17538

Author(s):

Sumita Trivedi ◽

Haocan Song ◽

Yuan Liu ◽

Conor Ernst Steuer ◽

William Stokes ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck ◽

Squamous Cell ◽

Disease Free Survival ◽

Squamous Cell Carcinomas ◽

Stage I ◽

Seer Database ◽

Free Survival ◽

Ajcc Staging ◽

Disease Free

e17538 Background: The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, incorporates significant changes to the prior seventh edition. The changes reflect the improved understanding of tumor biology, prognostic factors and molecular markers that effect outcomes in Head and Neck cancers. A key update restages OPSCC by human papilloma virus (HPV) positive and negative cancers as data demonstrated that these tumors have significantly different biology and outcomes. Methods: Using SEER data from 2004 – 2014, we identified male patients with squamous cell carcinomas of the tonsil, base of tongue and soft palate aged between 21 and 64 years old (those clinical characterizes were considered as surrogate markers for HPV positive status). We classified them by the AJCC 8th edition staging for HPV positive OPSCC and by AJCC 7th edition staging. The prediction performance by two staging editions were compared regarding overall survival (OS) and Disease free survival (DFS). Kaplan-Meier method and Cox proportional hazard model were applied, and the discrimination performance was measured by the concordance statistics (C-statistics). Results: A total of 8202 eligible patients were included in the analysis with a median follow up period of 51 months. 7415 (90.4%) patients had previously received radiation and 7038 (85.8%) patients had previously received chemotherapy. The median age of patients was 56 years. Distribution of stage I disease increased from 2% to 19.6% in AJCC 8th edition. 10-year overall survival (OS) for AJCC 8th stages I (74%), II (78%), III (55%) and IV (32%). Using Stage I as reference, the hazard ratio for stage II, III, and IV is 0.98 (95%CI: 0.87-1.09), 2.29 (95%CI: 2.04-2.57), and 5.88 (95%CI: 4.96-6.98). Similar results were noted for ten year disease free survival. The C-statistics measured overall discrimination for 8th edition is 0.68 and 0.63 for the 7th edition (P < 0.001). Conclusions: Based on this SEER analysis, the overall performance of discrimination improved from AJCC 7th to 8th edition; but in this study population, AJCC 8th edition does not distinguish stage I and II sufficiently as expected as it does for stages III and IV disease. Limitations of the SEER database include the surrogate for P16 status and under reported and incomplete data.

Download Full-text